Vaxart口服COVID-19疫苗清除了安全试验,进入了大规模阶段2b研究。 Vaxart's oral COVID-19 vaccine clears safety trial, advancing to a large-scale Phase 2b study.

Vaxart的口服避孕药COVID-19疫苗在对400名参与者进行的为期30天的研究中通过了初步安全评估,导致一个独立委员会建议进行第2b阶段试验,不作任何改动。 Vaxart's oral pill COVID-19 vaccine passed its initial safety assessment in a 30-day study of 400 participants, leading an independent board to recommend the Phase 2b trial proceed without changes. 试验将涉及10 000名参与者,目的是将疫苗的有效性和安全性与先前接种疫苗的成人中经核准的MRNA疫苗进行比较。 The trial, which will involve 10,000 participants, aims to compare the vaccine's effectiveness and safety against approved mRNA vaccines in previously immunized adults. Vaxart为这项研究获得的资金多达4.607亿美元。 Vaxart received up to $460.7 million in funding for this research.